Back |
home / stock / ifrx / ifrx message board
Subject | By | Source | When |
---|---|---|---|
znewcar1: IFRX 38% v8,6M c1.92 f44,2M H2.14 ML.94 HOD S1.81 | znewcar1 | investorshangout | 07/26/2022 9:24:07 PM |
znewcar1: IFRX 40% v5,7M c1.52 f44,2M H1.55 ML.78 | znewcar1 | investorshangout | 06/28/2022 8:09:47 PM |
znewcar1: IFRX 41% v120M c4.06 f44,1M Fwas28.4M$4.8 in 2020-1208 | znewcar1 | investorshangout | 10/28/2021 10:27:44 PM |
znewcar1: IFRX 18% v1,6M c4.79 f28,2M H4.98 | znewcar1 | investorshangout | 12/08/2020 11:23:36 PM |
EmergingGrowth: Why InflaRx (IFRX) Could Piggyback Off Regenerons Sudden Interest https://emerginggr | EmergingGrowth | investorshangout | 10/20/2020 6:37:21 PM |
znewcar1: IFRX 30% v3,0M c7.07 f26,1M H7.37 had R@6.5 got S6.16 | znewcar1 | investorshangout | 04/30/2020 8:50:52 PM |
znewcar1: IFRX 21% v2,7M c5.66 f26,1M H5.73 | znewcar1 | investorshangout | 04/03/2020 8:22:44 PM |
znewcar1: IFRX 49% v27,5M c5.73 f26,1M preMH@9.28 open@6 then reversed looking for S@5.15? | znewcar1 | investorshangout | 04/02/2020 1:25:16 AM |
News, Short Squeeze, Breakout and More Instantly...
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced today that GOHIBIC (vilobelimab) has been selected by the Biomedical Advanced Research and Development ...
Thought leaders in complement inhibition, chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) provide compelling new insights into the strong development rationales, potential differentiation and medical role of INF904 in initially targeted indications and inflammation & imm...
JENA, Germany, May 21, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced data presented at the American Thoracic Society (ATS) 2024 International Conference that is being held f...